-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vaccine-induced thrombotic thrombocytopenia (VITT) or thrombosis with thrombocytopenia syndrome (TTS) is a rare but serious complication
This single-center, continuous cohort study included all vaccinations based on (1) vaccination 4 to 21 days prior to symptom onset, (2) signs or symptoms of venous or arterial thrombosis, (3) thrombocytopenia < 150/nL, (4) antiplatelet factor 4 (PF4) antibody positive, and (5) elevated D-dimer > 4 times
Figure 1: D-dimer and platelet counts
Figure 2: D-dimer for individual patients
Eculizumab was successfully used in two patients with
In summary, VITT appears to be a highly prethrombotic lesion
Original Source:
Panagiota V, Dobbelstein C, Werwitzke S, Ganser A, Cooper N, Sachs UJ, Tiede A.